Genovis AB operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genovis AB with three other
companies in this sector in Sweden:
Xbrane Biopharma Ab
sales of 20.77 million Swedish Kronor [US$2.24 million]
of which 108%
was Long-acting injectables),
(20.69 million Swedish Kronor [US$2.24 million]
Sprint Bioscience AB
(23.97 million Swedish Kronor [US$2.59 million]
During the year ended December of 2017, sales at
Genovis AB were SEK 22.87 million (US$2.47 million).
increase of 23.3%
versus 2016, when the company's sales were SEK 18.54 million.
This was the third consecutive year of growth at Genovis AB.